Li Hao, Liu Ming-Fang, Liu Jian-Gang, Liu Long-Tao, Guan Jie, Cai Ling-Ling, Hu Jia, Wei Yun
Department of Geratology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China.
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2013 Jan;33(1):90-4.
To study the effects of Huannao Yicong Recipe (HNYCR)extract on the learning and memory ability, and the expressions of amyloid precursor protein (APP), beta-site APP-cleaving enzyme 1 (BACE1), presenilin-1 (PS-1), and beta amyloid protein (Abeta)in hippocampus CA1 area of APP transgenic mice, and to explore its mechanisms for treating Alzheimer's disease (AD).
Totally 3-month-old APP695V7171 transgenic mice were used to establish the AD model in this research. They were randomly divided into the model group, the Donepezil group, the large dose HNYCR extract group, the small dose HNYCR extract group, and the normal control group (C57BL/6J mice), 15 in each group. These animals were gavaged for 4 continuous months. Relevant indicators were detected: Morris water maze test was used to measure the spatial learning and memory ability. The immunohistochemical assay was used to detect the expressions of APP, BACE1, PS-1, and Abeta.
The times of crossing the original platform and the swimming time and distance in the fourth quadrant of the 7-month-old APP transgenic mice were significantly reduced in Morris water maze test, when compared with the normal control group (P < 0.01). The times of crossing original platform and the swimming time and distance in the fourth quadrant of all treatment groups significantly increased in Morris water maze test, when compared with the model group (P < 0.05). The expressions of APP, BACE1, PS-1, and Abeta in hippocampus CA1 area of 7-month-old model mice increased significantly (P < 0.01), when compared with the normal control group. The expressions of APP, BACE1, PS-1, and Abeta in each 7-month-old intervention groups were significantly reduced, when compared with the model group (P < 0.01).
Early application of HNYCR extract can obviously improve the learning and memory ability of APP transgenic mice that has declined, reduce the expressions of APP, BACE1, PS-1, and Abeta in the hippocampal CA1 area, reduce the production of Abeta, and slow down the pathological process of brains in APP transgenic mice.
研究还脑益聪方提取物对APP转基因小鼠学习记忆能力及海马CA1区淀粉样前体蛋白(APP)、β-分泌酶1(BACE1)、早老素-1(PS-1)和β淀粉样蛋白(Aβ)表达的影响,探讨其治疗阿尔茨海默病(AD)的机制。
本研究采用3月龄APP695V717I转基因小鼠建立AD模型,将其随机分为模型组、多奈哌齐组、还脑益聪方提取物大剂量组、还脑益聪方提取物小剂量组和正常对照组(C57BL/6J小鼠),每组15只。连续灌胃4个月,检测相关指标:采用Morris水迷宫试验测定空间学习记忆能力;采用免疫组织化学法检测APP、BACE1、PS-1和Aβ的表达。
Morris水迷宫试验中,7月龄APP转基因小鼠穿越原平台次数及在第四象限的游泳时间和距离,与正常对照组相比显著减少(P<0.01);各治疗组穿越原平台次数及在第四象限的游泳时间和距离,与模型组相比显著增加(P<0.05)。7月龄模型小鼠海马CA1区APP、BACE1、PS-1和Aβ的表达,与正常对照组相比显著增加(P<0.01);各7月龄干预组APP、BACE1、PS-1和Aβ的表达,与模型组相比显著降低(P<0.01)。
早期应用还脑益聪方提取物可明显改善已下降的APP转基因小鼠的学习记忆能力,降低海马CA1区APP、BACE1、PS-1和Aβ的表达,减少Aβ的产生,减缓APP转基因小鼠脑内的病理进程。